- Home
- DARE
DARE
Dare Bioscience Inc.
as 12-18-2024 3:34pm EST
Dare Bioscience Inc is a biopharmaceutical company committed to advancing innovative products for women's health. The company identifies, develops and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in advanced clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 31.9M | IPO Year: | N/A |
| Target Price: | $20.33 | AVG Volume (30 days): | 52.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.43 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.05 - $7.56 | Next Earning Date: | 11-14-2024 |
| Revenue: | $1,881,316 | Revenue Growth: | 88.13% |
| Revenue Growth (this year): | -49.78% | Revenue Growth (next year): | 136.52% |
Latest Dare Bioscience Inc. News
DARE Breaking Stock News: Dive into DARE Ticker-Specific Updates for Smart Investing
MT Newswires
2 days ago
Dare Bioscience to Submit Plan for Phase 3 Study of Potential Female Sexual Disorder Treatment
GlobeNewswire
2 days ago
Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD)
GlobeNewswire
8 days ago
Daré Bioscience Announces Publication in Sexual Medicine of Positive Findings from Demographic, Behavioral and Medication Use Subgroup Analyses in the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%
GlobeNewswire
14 days ago
Daré Bioscience Announces $2.5 Million Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
Thomson Reuters StreetEvents
a month ago
Q3 2024 Dare Bioscience Inc Earnings Call
GuruFocus.com
a month ago
Dare Bioscience Inc (DARE) Q3 2024 Earnings Call Highlights: Strategic Advancements and ...
Zacks
a month ago
Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates
GlobeNewswire
a month ago
Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update
Compare DARE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DARE Dare Bioscience Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.